C. diff nursing: assessment, isolation, and treatment guide

Clostridioides difficile (C. diff) is a spore-forming, toxin-producing bacterium that causes antibiotic-associated diarrhea and colitis – from mild loose stools to life-threatening toxic megacolon. In the United States, the CDC’s most recent national burden estimate is 462,100 cases in 2017, and the agency’s 2019 Antibiotic Resistance Threats report attributes 223,900 hospitalized cases and 12,800 deaths to C. diff in that same year, giving it an “urgent” threat designation. Healthcare-associated CDI has been falling – a 36% adjusted decline between 2011 and 2017 – while community-associated CDI has held steady, so the disease is shifting rather than disappearing. Nurses are the frontline defense: contact precautions with gloves and gowns, soap-and-water hand hygiene (alcohol-based hand rub does not remove spores), isolation compliance, stool monitoring, and fluid management are all primarily nursing responsibilities.

This reference covers pathophysiology, risk factors, severity classification, IDSA 2021 treatment guidelines, isolation precautions with the key NCLEX trap (alcohol vs. soap and water), nursing interventions, complications, and six NCLEX-style practice questions.

Fast-scan summary

What is C. diff and why nurses must know it

C. diff is one of the most common healthcare-associated infections in the United States, and the CDC classifies it as an urgent antimicrobial resistance threat. It thrives specifically when the normal gut flora is disrupted – most commonly by antibiotics – allowing C. diff to proliferate, produce toxins, and cause colitis ranging from mild self-limiting diarrhea to fulminant colitis with bowel perforation, septic shock, and death.

For nursing students, C. diff hits multiple NCLEX priority areas simultaneously: infection control and isolation precautions, pharmacology (vancomycin vs. metronidazole, fidaxomicin, anti-motility drug contraindications), fluid and electrolyte management, skin integrity, and escalation criteria. The single most tested nursing point is that alcohol-based hand rub does not kill C. diff spores, so soap and water is the expected answer after caring for a C. diff patient.

Pathophysiology

Spore formation and survival

C. difficile is a Gram-positive, obligate anaerobic bacillus. Its ability to form hardy, heat- and chemical-resistant spores is the key to its clinical significance. Spores can survive on environmental surfaces – bed rails, call buttons, bathroom fixtures – for months. They are resistant to most standard hospital disinfectants, including alcohol-based cleaners. Spores are ingested via the fecal-oral route, germinate into vegetative forms in the colon, and colonize the gut.

Disruption of the gut microbiome

In a healthy individual, the normal commensal gut flora (primarily Bacteroides, Lactobacillus, and Bifidobacterium species) competitively inhibit C. diff colonization. Antibiotics – particularly broad-spectrum agents – disrupt this microbial defense. Once colonization resistance is lost, C. diff vegetative cells proliferate and produce their two major toxins.

Toxin A and Toxin B

• Toxin A (TcdA) – enterotoxin: Binds to intestinal epithelial receptors, disrupts tight junctions, triggers an inflammatory cascade with neutrophil recruitment, and causes fluid secretion into the intestinal lumen. This produces the profuse watery diarrhea characteristic of CDI.
• Toxin B (TcdB) – cytotoxin: More potent than Toxin A. Inactivates Rho GTPases, causing cytoskeletal disruption and cell death. Responsible for the destruction of the intestinal epithelium. Both toxins work synergistically; Toxin B is considered the primary virulence factor in severe disease.

Pseudomembranous colitis

In severe CDI, the inflammatory destruction of the colonic mucosa leads to the formation of pseudomembranes – raised yellow-white plaques composed of fibrin, mucus, inflammatory cells, and necrotic epithelium. These plaques coat the colonic mucosa and are visible on colonoscopy. Pseudomembranous colitis indicates significant mucosal destruction and correlates with more severe clinical presentation.

Progression to toxic megacolon

In fulminant disease, the transmural inflammation and paralysis of the colon wall leads to toxic megacolon – colonic dilation >6 cm on plain X-ray with systemic signs of toxicity. The dilated, inflamed colon is at risk for perforation, leading to peritonitis, septic shock, and death. Toxic megacolon is a surgical emergency. For the sepsis progression pathway, see the sepsis nursing reference. For bowel perforation and peritonitis, see the peritonitis nursing reference.

Risk factors

Clinical presentation

CDI presentation exists on a spectrum from mild diarrhea to life-threatening fulminant colitis. Severity classification drives treatment decisions per IDSA 2021 guidelines.

Non-severe CDI

• Watery, non-bloody diarrhea: ≥3 loose stools per 24 hours
• Diffuse, crampy abdominal pain – often worse after meals
• Low-grade fever (38–38.5°C / 100.4–101.3°F)
• Normal WBC or mild leukocytosis (WBC ≤15,000 cells/μL)
• Serum creatinine <1.5 mg/dL
• Nausea, malaise, reduced appetite
• Onset typically within 5–10 days of antibiotic initiation; can occur up to 8 weeks after stopping antibiotics

Severe CDI

All of the above plus any of the following:

• WBC ≥15,000 cells/μL – marked leukocytosis suggests significant systemic inflammatory response
• Serum creatinine >1.5 mg/dL – indicates volume depletion or early acute kidney injury (IDSA/SHEA 2017 uses this absolute value; ACG 2021 uses the same WBC and creatinine cut points)
• Increasing abdominal pain and distension
• Profuse diarrhea (may exceed 10 loose stools/day)
• Higher fever

For electrolyte imbalances (hypokalemia, hyponatremia, metabolic acidosis) from stool losses, see the dedicated reference. For lab value interpretation including WBC and creatinine thresholds, see the nursing lab values cheat sheet.

Fulminant CDI (highest severity)

Any of the following:

• Hypotension or septic shock (SBP <90 mmHg, vasopressor requirement)
• Ileus – absence of bowel sounds, abdominal distension, obstipation
• Toxic megacolon – colonic dilation >6 cm on imaging, systemic toxicity
• Bowel perforation (peritoneal signs, free air on X-ray)

Fulminant CDI requires emergent surgical consultation. For the GI bleeding that can complicate pseudomembranous colitis, see the GI bleed nursing reference.

NCLEX tip – recognizing fulminant deterioration

A patient with CDI who suddenly stops having diarrhea and develops abdominal distension and worsening vital signs is a CRITICAL red flag. Cessation of diarrhea in the context of ileus or megacolon indicates the colon is no longer moving – this is deterioration, not improvement. Notify the provider immediately.

Severity classification and treatment

Key pharmacology points for NCLEX

Oral vancomycin: For CDI, oral vancomycin acts locally within the gut lumen and is minimally absorbed – it does not achieve systemic levels or treat systemic infection. IV vancomycin has no role in CDI treatment. This is the opposite of vancomycin use for MRSA (IV for systemic infection). See the MRSA nursing reference for contrast.

Metronidazole (Flagyl): No longer recommended as monotherapy for an initial episode of CDI per the IDSA/SHEA 2021 focused update, due to inferior cure rates against both fidaxomicin and vancomycin. Its remaining role is IV administration in fulminant disease, combined with high-dose oral vancomycin. It may still be used orally as an alternative for non-severe disease if neither preferred agent is available.

Fidaxomicin (Dificid): Narrow-spectrum macrocyclic antibiotic; stays local in the gut; spares Bacteroides and other normal flora more than vancomycin, leading to lower recurrence rates. The IDSA/SHEA 2021 focused update suggests it over vancomycin for both an initial episode and a first recurrence, a conditional recommendation the guideline itself acknowledges is constrained by cost and availability. Many institutions still start with vancomycin for that reason, which the guideline permits.

Bezlotoxumab (Zinplava): Monoclonal antibody against C. diff Toxin B, given as a single IV infusion alongside standard antibiotics to reduce recurrence in high-risk patients. Merck discontinued Zinplava in January 2025 and there is no generic or biosimilar, so it is no longer an available option in US practice. Older question banks and textbooks still list it – recognize the mechanism, but do not expect it on a current formulary.

Microbiota restoration therapies: Two FDA-approved live biotherapeutics now exist for preventing recurrence after antibiotic treatment of recurrent CDI in adults 18 and older – Rebyota (fecal microbiota, live-jslm; approved November 30, 2022; single 150 mL rectal suspension) and Vowst (fecal microbiota spores, live-brpk; approved April 26, 2023; oral capsules). Conventional fecal microbiota transplantation by colonoscopy or enema remains in use where a licensed product is unavailable, with reported cure rates around 80–90% in recurrent CDI. All of these follow a course of antibiotics rather than replacing it.

AVOID anti-motility agents: Loperamide (Imodium), diphenoxylate-atropine (Lomotil), and opioids decrease colonic motility, trapping toxins in the colon and increasing the risk of toxic megacolon. They are contraindicated in CDI.

Diagnostic workup

Stool collection nursing priorities:

• Test the right patient. IDSA/SHEA 2017 targets testing at patients with new, unexplained diarrhea – 3 or more unformed stools in 24 hours. Check the MAR for laxatives, stool softeners, and new tube feeds first; the SHEA 2022 update notes it may be reasonable to hold laxatives and watch for resolution before sending a sample.
• Unformed stool only. Labs reject formed stool, because a positive result in a patient without diarrhea usually reflects colonization.
• No repeat testing within 7 days during the same episode of diarrhea (IDSA/SHEA 2017, strong recommendation).
• No test of cure. Do not test stool from asymptomatic patients after treatment; patients can stay PCR-positive for weeks after clinical cure.

Isolation precautions (NCLEX critical)

Contact precautions protocol

C. diff requires standard precautions PLUS contact precautions:

• Private room with a dedicated toilet or commode – if private rooms are limited, prioritize patients with stool incontinence; if cohorting is unavoidable, cohort only with patients who have the same organism(s) (do not cohort CDI patients who differ in MRSA or VRE status)
• Gown AND gloves required on room entry, before touching the patient or any surface; don before entering, remove before exiting; perform hand hygiene immediately after removing gloves
• Dedicated equipment – dedicated stethoscope, blood pressure cuff, thermometer remain in the room; do not share between patients
• Contact precautions sign on the door – alert all staff and visitors
• Visitor education – teach visitors gown and glove requirements and hand hygiene with soap and water before leaving the room

The single most important NCLEX rule: soap and water, not alcohol

Alcohol-based hand rubs (ABHR) do NOT kill C. diff spores. Spores are resistant to alcohol. After caring for a C. diff patient – or after removing gloves – wash with soap and water. CDC’s healthcare hand hygiene guidance calls for rubbing hands vigorously for at least 15 seconds, and notes that the 20 seconds used in public guidance is also acceptable. Soap and water physically remove spores from hands through friction; they do not kill spores but dislodge them into the water stream.

What the guidelines say in full: IDSA/SHEA 2017 accepts either soap and water or ABHR in routine (endemic) settings, prefers soap and water during outbreaks or sustained high rates, and prefers it after direct contact with feces or the perineal area. CDC’s healthcare guidance encourages soap and water during C. diff outbreaks and stresses that glove and gown use is the real priority, because gloves keep spores off hands in the first place. Many hospitals require soap and water for every C. diff room regardless. On NCLEX, choose soap and water.

This is a classic NCLEX trap: options offering “use alcohol hand gel after removing gloves” are incorrect for C. diff. Soap and water is the correct answer every time. For comparison, see the MRSA nursing reference – MRSA is killed by alcohol and does not require soap and water specifically (though soap and water is always acceptable).

Environmental cleaning

Standard quaternary ammonium compounds (quats) – the most common hospital surface disinfectants – do not kill C. diff spores. Most hospitals use a sporicidal protocol for CDI rooms:

• Sporicidal agents: a 1:10 dilution of household bleach (sodium hypochlorite) or another product on the EPA’s List K with a C. diff spore claim, used at the label’s contact time. The SHEA 2022 update lists sporicidal disinfection as an added measure for outbreak and hyperendemic settings, and IDSA/SHEA 2017 advises considering sporicidal terminal cleaning during high endemic rates, outbreaks, or repeated cases in the same room
• Enhanced terminal cleaning of rooms after discharge or transfer
• All horizontal surfaces, high-touch areas (call buttons, bed rails, bathroom fixtures, IV poles)
• Disposable cleaning equipment preferred; do not share mop heads or cloths between rooms

Duration of precautions

CDC’s general isolation table and its C. diff-specific guidance give different stopping points, so attribute each to its source:

• CDC isolation guideline, Appendix A (the 2007 table, updated September 2026): Contact + Standard Precautions for the duration of illness. IDSA/SHEA 2017 cites this as CDC’s position.
• IDSA/SHEA 2017 (recommendation XVI): continue Contact Precautions for at least 48 hours after diarrhea has resolved (weak recommendation, low-quality evidence), because skin and environmental contamination is still common when diarrhea stops. CDC’s current C. diff prevention guidance for acute care facilities (updated May 2026) gives the same “at least 48 hours after diarrhea has resolved, or longer” rule, and the SHEA 2022 compendium repeats it.
• Until discharge: IDSA/SHEA 2017 suggests prolonging precautions until discharge if CDI rates stay high despite standard control measures, and SHEA 2022 lists it as an additional approach, since no data show that routine extension lowers CDI incidence. Some hospitals apply it to every CDI patient.
• For NCLEX and most hospital policies, the working rule is at least 48 hours after the last diarrheal stool; follow your facility’s policy if it is longer.
• Test-of-cure stool samples are NOT recommended after successful treatment – resolution of symptoms guides discontinuation

Nursing interventions

Complications and monitoring

NCLEX-style practice questions

Question 1

A nurse is caring for a patient admitted with confirmed C. difficile infection. After removing gloves following perianal care, which action should the nurse take?

• A. Apply alcohol-based hand rub for at least 15 seconds
• B. Wash hands with soap and water, scrubbing for at least 20 seconds
• C. Apply alcohol-based hand rub followed by soap and water
• D. Use hand sanitizer with at least 70% alcohol concentration

Correct answer: B

Rationale: Alcohol-based hand rubs do not kill C. diff spores. Spores are resistant to alcohol-containing products. Soap and water physically removes spores from the hands through friction and rinsing – the mechanical action dislodges spores rather than killing them. This is the most critical nursing knowledge point for C. diff infection control. Options A, C, and D are incorrect because they include or rely on alcohol, which is ineffective against C. diff spores.

Question 2

A patient with C. difficile infection has a WBC of 18,500 cells/μL and a serum creatinine of 1.8 mg/dL (baseline 1.0 mg/dL). Which classification correctly describes this patient?

• A. Non-severe CDI – standard treatment with oral metronidazole
• B. Severe CDI – treatment with oral vancomycin or fidaxomicin
• C. Fulminant CDI – requires emergent surgical consultation
• D. Non-severe CDI – treatment with oral vancomycin 125 mg QID

Correct answer: B

Rationale: Per the IDSA/SHEA severity criteria (2017 guideline, carried into the 2021 focused update), severe CDI is defined by WBC ≥15,000 cells/μL OR serum creatinine >1.5 mg/dL. This patient meets both criteria (WBC 18,500; SCr 1.8 mg/dL, above the 1.5 mg/dL threshold). The threshold is an absolute creatinine value, so a patient whose creatinine has risen from a low baseline can still fall below it. Treatment for severe CDI is fidaxomicin 200 mg BID × 10 days (suggested by IDSA/SHEA) or oral vancomycin 125 mg QID × 10 days as an acceptable alternative – NOT metronidazole, which is no longer first-line. Fulminant CDI requires hypotension/shock, ileus, or toxic megacolon, which are not described.

Question 3

A nurse enters the room of a patient on contact precautions for C. difficile to deliver oral medications. Which sequence of PPE use is correct?

• A. Apply gloves → enter room → apply gown → administer medication → remove gown → remove gloves → use alcohol hand rub
• B. Apply gown → apply gloves → enter room → administer medication → remove gloves → remove gown → wash hands with soap and water
• C. Enter room → apply gown → apply gloves → administer medication → remove gloves → remove gown → use alcohol hand rub
• D. Apply gloves → enter room → administer medication → remove gloves → use alcohol hand rub → remove gown

Correct answer: B

Rationale: Contact precautions require donning gown THEN gloves outside the room, before entry. On exit: remove gloves first (most contaminated item), then gown, then perform hand hygiene with soap and water – not alcohol-based hand rub, as alcohol is ineffective against C. diff spores. Option A has incorrect donning order (gloves before gown). Option C violates the rule against entering the room before donning PPE. Option D is incorrect in both sequence and hand hygiene method.

Question 4

A patient with severe C. difficile infection who has been having 8–10 liquid stools per day suddenly reports that diarrhea has stopped. The nurse assesses abdominal distension, absent bowel sounds, and fever of 39.2°C. What is the nurse’s priority action?

• A. Document the improvement in stool frequency as a sign of treatment response
• B. Administer loperamide (Imodium) as needed for diarrhea control
• C. Notify the provider immediately – these findings suggest toxic megacolon
• D. Obtain a repeat stool C. diff PCR to assess for test-of-cure

Correct answer: C

Rationale: Cessation of diarrhea in a patient with severe CDI combined with abdominal distension, absent bowel sounds, and fever is a critical red flag for toxic megacolon or ileus – not improvement. The colon is failing to propel stool, and the dilation creates risk of perforation and septic shock. Immediate provider notification and imaging are required. Loperamide (Option B) is contraindicated in CDI and would worsen toxic megacolon. Test-of-cure stool testing (Option D) is not recommended by IDSA after CDI treatment.

Question 5

A provider orders a stool specimen for C. difficile testing. When the nurse enters the patient’s room, the patient reports having a formed bowel movement. What should the nurse do?

• A. Collect the formed stool immediately and send it to the lab in a sealed container
• B. Document the stool as formed and do not collect at this time; inform the provider
• C. Add water to the stool sample to approximate a liquid consistency before sending
• D. Collect the formed stool only if the patient also has abdominal cramping

Correct answer: B

Rationale: C. diff PCR and toxin assays should only be performed on unformed (diarrheal) stool. Formed stool testing yields high rates of false positives because C. diff may be present as a colonizer without causing active infection in patients who have formed stool. Labs typically reject formed stool samples. The nurse should document the stool consistency, not collect the specimen, and inform the provider that the patient currently has formed stool. Adding water (Option C) is inappropriate and would adulterate the specimen.

Question 6

A nurse is discharging a patient who was hospitalized with C. difficile infection. Which statement by the patient indicates the need for further teaching?

• A. “I should tell any future healthcare providers that I had C. diff.”
• B. “If I get diarrhea again in the next two months, I should see a doctor right away.”
• C. “I can use my regular hand sanitizer when I get home – that will prevent spreading it to my family.”
• D. “I should avoid unnecessary antibiotics in the future.”

Correct answer: C

Rationale: This statement requires correction. Alcohol-based hand sanitizers do not kill C. diff spores. The patient should be instructed to wash hands with soap and water after using the toilet and before preparing food to reduce fecal-oral transmission to household contacts. Bathroom surfaces should be cleaned with bleach-based products. Options A, B, and D all reflect accurate understanding: informing future providers of CDI history prevents prescribers from inadvertently re-exposing the patient to high-risk antibiotics; recurrence within 8 weeks is common and requires prompt treatment; antibiotic stewardship reduces CDI risk.

Key takeaways for nursing practice

• C. diff remains an urgent CDC threat: an estimated 462,100 US cases in 2017, with 223,900 hospitalized cases and 12,800 deaths, driven by antibiotic disruption of the gut microbiome and environmental spore burden. Healthcare-associated cases have fallen substantially since 2011; community-associated cases have not.
• Isolation is immediate: Apply contact precautions on suspicion, before confirmatory testing returns.
• Soap and water after C. diff care: Alcohol hand rub will not kill or reliably remove spores. Gloves and gowns are the first barrier; wash with soap and water after removing them, and pick soap and water on NCLEX.
• Know the IDSA 2021 preference order: fidaxomicin is suggested first for an initial episode and a first recurrence, oral vancomycin is an acceptable alternative, and metronidazole has dropped out of first-line use except as an IV adjunct in fulminant disease. High-dose oral vancomycin remains the backbone of the fulminant regimen.
• Never give anti-motility agents: Loperamide and diphenoxylate are contraindicated – they can precipitate toxic megacolon.
• Watch for the paradox: Diarrhea stopping in a CDI patient can mean ileus or megacolon – escalate immediately.
• Recurrence is common: 10–30% of patients have at least one recurrence after a first episode, and the risk rises with each recurrence; fidaxomicin, vancomycin tapers, and microbiota-based therapies are the tools for recurrent disease.

References

1. Centers for Disease Control and Prevention. Clostridioides difficile (C. diff). CDC; updated 2024. https://www.cdc.gov/cdiff/
2. Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021;73(5):e1029–e1044. doi:10.1093/cid/ciab549. PMID: 34164674.
3. McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48. doi:10.1093/cid/cix1085. PMID: 29462280.
4. Guh AY, Mu Y, Winston LG, et al. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. N Engl J Med. 2020;382(14):1320–1330. doi:10.1056/NEJMoa1910215. PMID: 32242357.
5. Kelly CR, Fischer M, Allegretti JR, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021;116(6):1124–1147. doi:10.14309/ajg.0000000000001278. PMID: 34003176. (Supersedes the 2013 ACG guideline by Surawicz et al.)
6. Wilcox MH, Gerding DN, Poxton IR, et al.; MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305–317. doi:10.1056/NEJMoa1602615.
7. Bakken JS, Borody T, Brandt LJ, et al.; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044–1049. doi:10.1016/j.cgh.2011.08.014.
8. Oughton MT, Loo VG, Dendukuri N, Fenn S, Libman MD. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile. Infect Control Hosp Epidemiol. 2009;30(10):939–944. doi:10.1086/605322.
9. Kociolek LK, Gerding DN, Carrico R, et al. Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2023;44(4):527–549. doi:10.1017/ice.2023.18. PMID: 37042243. (Supersedes the 2014 SHEA compendium by Dubberke et al.)
10. Herdman TH, Kamitsuru S, Lopes CT, eds. NANDA International Nursing Diagnoses: Definitions and Classification, 2024–2026. 13th ed. Thieme; 2024.
11. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. US Department of Health and Human Services, CDC; 2019. Clostridioides difficile section: 223,900 estimated cases in hospitalized patients and 12,800 estimated deaths, 2017; threat level Urgent.
12. Centers for Disease Control and Prevention. Clinical Safety: Hand Hygiene for Healthcare Workers. CDC; accessed October 2026. ABHS preferred in most clinical situations; soap and water during C. difficile outbreaks; rub hands at least 15 seconds when washing. https://www.cdc.gov/clean-hands/hcp/clinical-safety/index.html
13. US Food and Drug Administration. REBYOTA (fecal microbiota, live-jslm). Approved November 30, 2022. https://www.fda.gov/vaccines-blood-biologics/vaccines/rebyota
14. US Food and Drug Administration. VOWST (fecal microbiota spores, live-brpk). Approved April 26, 2023. https://www.fda.gov/vaccines-blood-biologics/vowst
15. American Society of Health-System Pharmacists. Drug shortage detail: bezlotoxumab injection (ZINPLAVA, Merck) – discontinued January 2025; Merck was the sole supplier. ASHP Drug Shortages database; bulletin February 5, 2025.
16. Centers for Disease Control and Prevention; Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions, Appendix A: type and duration of precautions recommended for selected infections and conditions (Clostridioides difficile and gastroenteritis rows: Contact + Standard, duration of illness; soap and water preferred because alcohol lacks sporicidal activity). Updated September 11, 2026. Accessed October 21, 2026. https://www.cdc.gov/infection-control/hcp/isolation-precautions/appendix-a-type-duration.html
17. Centers for Disease Control and Prevention. Clinical guidance for C. diff infection prevention in acute care facilities (maintain contact precautions for at least 48 hours after diarrhea has resolved, or longer; single room with dedicated toilet; EPA List K sporicidal cleaning). Updated May 13, 2026. Accessed October 21, 2026. https://www.cdc.gov/c-diff/hcp/clinical-guidance/index.html